[Ip-health] The Medicines Patent Pool sublicenses sutezolid, an investigational drug for TB treatment, paving the way for clinical development

Sophie Thievenaz sthievenaz at medicinespatentpool.org
Wed Dec 9 07:00:14 PST 2020


Dear colleagues,

The Medicines Patent Pool and the Bill & Melinda Gates Medical Research Institute signed an agreement today to advance the development of investigational sutezolid-containing TB drug regimens, especially for low- and middle-income countries, where most people with TB live. The drug candidate sutezolid, in combination with other drugs, could potentially be used as an all-oral, shortened regimen for all forms of TB, including multidrug-resistant TB.

Read full statement here: https://medicinespatentpool.org/news-publications-post/mpp-gates-mri-sublicence-agreement-news-dec-2020/

You can also read it below:

Geneva and Cambridge MA – The Medicines Patent Pool (MPP) and the Bill & Melinda Gates Medical Research Institute<https://www.gatesmri.org/> (Gates MRI) signed an agreement today to advance the development of investigational sutezolid-containing TB drug regimens, especially for low- and middle-income countries, where most people with TB live. The drug candidate sutezolid, in combination with other drugs, could potentially be used as an all-oral, shortened regimen for all forms of TB, including multidrug-resistant TB (MDR-TB).

In October 2019, MPP and Pfizer entered into a licence agreement<https://medicinespatentpool.org/news-publications-post/the-medicines-patent-pool-and-pfizer-sign-licence-for-access-to-key-data-on-investigational-tuberculosis-treatment-sutezolid/>, which granted MPP rights to sublicense to third parties the patents and know-how relating to the use of sutezolid (formerly known as PNU-100480), a promising antibiotic drug candidate, in combination with other agents for the prevention and/or treatment of TB. Gates MRI is the first recipient of such a sublicence. The sublicence<https://medicinespatentpool.org/licence-post/sutezolid-pfizer/> allows Gates MRI to access Pfizer’s existing preclinical, phase 1 and phase 2a clinical study data and results with the aim of further developing this potential component of future TB regimens, should the data be supportive.

“We need better TB treatments in our arsenal to address the resistant strains of TB bacteria,” said MPP’s Executive Director Charles Gore. “If we are to outpace this killer disease that claims 4,500 lives every day, we need to have promising drugs in the TB R&D pipeline at all times. Sutezolid is one such candidate and MPP is excited that Gates MRI is undertaking development program to study it for TB.”

“Gates MRI is proud to sublicense sutezolid from MPP. We look forward to studying this promising drug candidate, consistent with our ultimate goal to accelerate the end of TB and in the interim, bring hope to the millions suffering from this serious infectious disease. We intend to pursue development of a TB regimen that may include sutezolid as we attempt to tackle drug-sensitive and drug-resistant tuberculosis,” said Dr. Charles Wells, Clinical Development Leader at the Bill & Melinda Gates Medical Research Institute.

According to the World Health Organization, TB is one of the top 10 causes of death worldwide. In 2019, 10 million people fell ill with TB, and 1.4 million<https://www.who.int/news-room/fact-sheets/detail/tuberculosis> died from the disease. MDR-TB remains a public health crisis and a health security threat, with nearly 465,000<https://www.who.int/news-room/fact-sheets/detail/tuberculosis> incident cases in 2019.

For more information:
Gelise MCCULLOUGH | +41 79 685 64 36 | press at medicinespatentpool.org<mailto:press at medicinespatentpool.org>


Sophie Thievenaz | Communications Manager | Medicines Patent Pool
Rue de Varembé 7, 1202 Geneva, Switzerland
Mob: +33 6 87 54 60 37
E-mail: sthievenaz at medicinespatentpool.org<mailto:sthievenaz at medicinespatentpool.org>




More information about the Ip-health mailing list